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Antenatal synthetic glucocorticoids promote fetal maturation in pregnant women at risk of preterm
delivery and their mechanism of action may involve other endocrine systems. This study investigated
the effect of maternal dexamethasone treatment, at clinically relevant doses, on components of the
renin-angiotensin system(RAS) in thepregnanteweandfetus. From125daysofgestation (term,145
2 d), 10 ewes carrying single fetuses of mixed sex (3 female, 7 male) were injected twice im, at 10–11
PM, with dexamethasone (2 12mg, n 5) or saline (n 5) at 24-hour intervals. At 10 hours after the
secondinjection,maternaldexamethasonetreatmentincreasedangiotensin-convertingenzyme(ACE)
mRNA levels in the fetal lungs, kidneys, and heart andACE concentration in the circulation and lungs,
but not kidneys, of the fetuses. Fetal cardiac mRNA abundance of angiotensin II (AII) type 2 receptor
decreased aftermaternal dexamethasone treatment. Between the two groups of fetuses, therewere
no significant differences in plasma angiotensinogen or renin concentrations; in transcript levels of
renalrenin,orAII type1or2receptors inthelungsandkidneys;or inpulmonary,renalorcardiacprotein
content of the AII receptors. In the pregnant ewes, dexamethasone administration increased pulmo-
nary ACE and plasma angiotensinogen, and decreased plasma renin, concentrations. Some of the
effects of dexamethasone treatment on the maternal and fetal RAS were associated with altered
insulin and thyroid hormone activity. Changes in the local and circulating RAS induced by dexameth-
asone exposure in utero may contribute to the maturational and tissue-specific actions of antenatal
glucocorticoid treatment. (Endocrinology 156: 3038–3046, 2015)
In clinical practice, synthetic glucocorticoids, such asdexamethasone, are administered routinely to pregnant
womenat riskofpretermdelivery inorder topromote fetal
maturation and neonatal survival (1, 2). These drugs
mimic the normal rise in endogenous glucocorticoids seen
in the fetus near term by promoting structural and func-
tional changes in fetal tissues in preparation for life after
birth (3). Over the last 40 years, antenatal glucocorticoid
therapyhas improved survival of the premature infant and
has reduced markedly the incidence of many disorders
associated with preterm delivery, such as respiratory dis-
tress syndrome (2, 4). The clear beneficial effects of ma-
ternal glucocorticoid treatmenthavebeenoffset, however,
by evidence showing adverse consequences for growth and
long-term blood pressure (BP) control, especially in infants
exposed to multiple doses in utero (5–7). It is therefore im-
portant to understand themechanisms of glucocorticoid ac-
tion in the control of fetal growth and maturation.
Some of the effects of the glucocorticoids on the devel-
opment of fetal tissues are mediated, in part, by other
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endocrine systems (8, 9). For example, in fetal sheep, en-
dogenous and synthetic glucocorticoids stimulate the pro-
duction of the active thyroid hormone, T3, and in turn, T3
promotes hepatic glycogen deposition and gluconeogenic
enzymeactivity inpreparation forbloodglucose control at
birth (10–13). The renin-angiotensin system (RAS) is
functional in the fetus from relatively early in gestation
(14, 15) and is known to have an important role in the
growth and development of specific tissues, as well as in
the regulation of renal and cardiovascular function in utero
(16–18). A number ofmaturational changes are observed in
the fetal RAS near term, some of which are regulated by the
prepartum surge in endogenous glucocorticoids (19–22). In
addition, direct administration of dexamethasone to the
sheep fetus increases both pulmonary and circulating con-
centrations of angiotensin-converting enzyme (ACE) in as-
sociation with a rise in fetal arterial BP (23). However, the
effectofmaternaldexamethasonetreatment, inaregimesim-
ilar to that used in clinical practice, on the components of the
RAS in the pregnant mother and fetus during late gestation
is unknown in any species.
Therefore, the aim of this study was to investigate the
acute effect of maternal dexamethasone treatment, in clini-
cally relevantdoses,onvariouscomponentsof theRASinthe
pregnant ewe and fetus. The study hypothesized that syn-
thetic glucocorticoid administration to the pregnant ewe
would stimulate components of both the maternal and fetal
RAS with potential consequences for fetal development.
Materials and Methods
Animals
Ten Welsh Mountain ewes carrying singleton fetuses of
known gestational age were used in this study. There were 3
female and 7 male fetuses. The ewes were maintained on 200 g
kg1 concentrates daily (sheep nuts number 6; 18% protein and
10 MJ/kg; H & C Beart Ltd) with free access to hay, water and
a salt-lick block. All experimental procedureswere carried out in
accordance with the United Kingdom Animals (Scientific Proce-
dures) Act 1986 and approved by the research ethics committee
at the University of Cambridge.
Experimental procedures
From125days of gestation, all of the eweswere injected twice
im with either dexamethasone (2 12 mg in 2-mL 0.9%NaCl,
n 5) or saline (2-mL 0.9% NaCl, n 5) at 24-hour intervals.
The experimental regime of dexamethasone treatment was sim-
ilar to that recommended in human clinical practice by theRoyal
College of Obstetricians and Gynaecologists (24). At 10 hours
after the second injection, the fetusesweredeliveredby caesarean
section under general anesthesia (20 mg kg1 sodium pentobar-
bitone iv). This time pointwas chosen so that datawere obtained
when the fetal dexamethasone concentration was comparable
with previous studies that examined the cardiovascular effects of
1) maternal dexamethasone treatment and 2) direct fetal dexa-
methasone infusion in chronically catheterized fetuses (25, 26).
The plasma dexamethasone concentration in the sheep fetus at
this time point was approximately one-fifth of that measured in
umbilical arterial blood samples taken from human infants at
caesarean section after maternal dexamethasone treatment (27).
Before anesthesia at between 9 and 10 AM, 10-mL blood samples
were obtained from the ewes by jugular venepuncture. At deliv-
ery, 10-mL blood samples were taken by venepuncture of the
umbilical artery, and a number of tissueswere collected from the
ewes and fetuses after the administration of a lethal dose of bar-
biturate (200 mg kg1 sodium pentobarbitone iv). Samples of
lung, kidney, and heart from the fetus, and lung and kidney, but
not heart, from the ewe, were immediately frozen in liquid ni-
trogen and stored at 80°C until analysis.
Biochemical analyses
Plasma hormone concentrations
All blood samples were immediately placed into EDTA-con-
taining tubes and centrifuged for 5 minutes at 1000g and 4°C.
The plasma aliquotswere stored at20°Cuntil analysis. Plasma
angiotensinogen and renin concentrations were measured by
RIA as described previously (28, 29). The lower limits of detec-
tion were 0.01 g mL 1 for angiotensinogen and 0.5 pg mL1
h1 for renin. Plasma concentrations of cortisol, T4, T3, and
insulin were measured by RIA or ELISA as detailed and pub-
lished in these animals previously (12, 30).
RAS protein concentrations
Tissue and plasma ACE concentrations (as a proxy measure
of activity) were determined by a spectrophotometric enzyme
assayasdescribedpreviously (20, 22).TissueACEconcentration
was expressed as nanomoles of hippurate generated per min per
mgprotein,whereasplasmaACEconcentrationwasmeasured in
U l1 where 1 U equals 1 mol of hippurate generated in 1
minute. Protein levels of the angiotensin (AII) type 1 receptor
(AT1R) and AT2R subtypes were determined in maternal lung
and renal cortex, and fetal lung, heart, and renal cortex, byWest-
ern blotting as detailed previously (31). The primary antibodies
used were both rabbit polyclonal antibodies to epitopes on the
human AT1R (0.2-g/mL 306, sc-579; Santa Cruz Biotechnol-
ogy, Inc) and the human AT2R (0.04-g/mL H-143, sc-9040;
Santa Cruz Biotechnology, Inc) (Supplemental Table 1). Mem-
branes were analyzed with Ponceau S to normalize for protein
loading as validated previously (32). Proteins were quantified
using ImageJ software (National Institutes of Health; http://rsb.
info.nih.gov/ij/), and ratios of protein contentwere arcsine trans-
formed before statistical analysis.
RAS mRNA abundance
TissuemRNAabundanceof renin,ACE,AT1R,andAT2Rwere
measured by TaqMan quantitative RT-PCR. Frozen samples of
tissue (15mg)were placed inLysingMatrix-D tubes (MPBiomedi-
cals) with 170-L lysis/binding solution from aMagMax96 Total
RNA Isolation kit (Life Technologies) and 0.75-L -mercapto-
ethanol, and homogenized using a FastPrep-24 (MP Biomedicals).
After homogenisation, 106-L 100% isopropanol was added to
each sample. Sampleswere placed into aMagMAX96 system (Ap-
plied Biosystems) where RNAwas isolated and deoxyribonuclease
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(DNase)-treated (TURBO DNase) using the MagMAX96 Total
RNA Isolation kit (Life Technologies). Sample RNA yields and
purities were assessed by aNanodrop (Thermo Fisher). Ratios of ab-
sorption (260/280nm) of all preparations were between 1.8 and 2.0.
Reverse transcription of mRNAwas carried out using a PCR
Express machine (Thermo Fisher) and materials from Promega
and Invitrogen. For each sample, 5 L of DNase-treated RNA
was mixed with 1-L random primers, 1-L deoxyribonucleo-
tide triphosphate mix, and 5-L ribonuclease-free water, and
incubated at 65°C for 2 minutes. A master reverse transcription
mix was made, consisting of 4-L first strand buffer, 2-L di-
thiothreitol, 1-L RNaseOUT, and 1-L Superscript II enzyme.
The samples were incubated at room temperature for 5 minutes,
at 42°C for 50 minutes and at 70°C for 15 minutes.
TaqMan quantitative real-time polymerase chain reaction
(qRT-PCR) was performed to measure mRNA abundance of
target genes in tissue samples. Samples were analyzed using a
TaqMan 7900HT and data were acquired and processed with
Sequence Detector version 2.3 software (Applied Biosystems).
TaqMan Master Mix (5 L), 0.5-L target gene probe and
primer set, and 3.5-L water, were added to each well of a 96-
well high-throughput plate (Applied Biosystems). In addition,
1-L tissue cDNA at 1:20 dilution was added to each well apart
from the nontemplate controls, where 1 L of water was added.
The sequences of the TaqMan qRT-PCR probes for renin, ACE,
AT1R, and AT2R are listed in Table 1. Each tissue sample was
measured in triplicate and normalized to the geometric mean of
2 housekeeping genes, glyceraldehyde 3-phosphate dehydroge-
nase, and cyclophilin A (Table 1). The mRNA levels of these
housekeeping genes were not affected by maternal dexametha-
sone treatment. For eachassay, anegative controlwithout cDNA
was included to ensure that amplicon contamination had not
occurred in the reaction. Cycle thresholds determined by qRT-
PCRwere analyzed by the delta-delta-cycle thresholdmethod as
all standard curves were linear and parallel.
Statistical analyses
A sample size of 5 animals was calculated in order to find a
2-fold difference in fetal pulmonary ACE concentration, assum-
ing a SD of 0.26, and to achieve 99% power at the 5% signifi-
cance level. This sample size calculation was based onmean and
SD values measured in previous studies from this laboratory
examining the effects of fetal dexamethasone treatment on pul-
monaryACEconcentration (23) (Sigmastat 3.5; Systat Software,
Inc). All data are presented asmean SEM. The distributions of
data for plasmaand tissuemeasurements
were assessed for normality by the Kol-
mogorov-Smirnov test, and compared
between the treatment groups by Stu-
dent’s unpaired t test (parametric) or
Mann-Whitney test (nonparametric), as
appropriate. Relationships between the
variables measured were determined by
Pearson correlation and partial correla-
tion analyses. The null hypothesis was
rejected where P  .05.
Results
Fetus
Within 10 hours of the secondma-
ternal injectionofdexamethasone, the
fetal plasma concentration of ACE in-
creased significantly (P .05) (Figure
1A).Plasmacortisoldecreased,andT3
and insulin concentrations increased
in the fetuses exposed to dexametha-
Figure 1. Plasma concentrations of angiotensinogen, renin, and ACE in the fetuses (A) and
ewes (B) sampled at 10 hours after the second daily injection of either saline (, n  5) or
dexamethasone ( , n  5). Data are presented as mean values (SEM). Significant difference
from saline-treated group: *, P  .05; †, P  .06.
Table 1. Primer and Reporter Sequences Used for TaqMan qRT-PCR in the Sheep
Gene Forward Primer Sequence Reverse Primer Sequence Reporter Sequence
Reporter
Dye
Renin GGATCTGGGAAGGTCAAAGGTTTC CGCCAAAGGTCTGTGTGACT CCGCCCACAGTCACC FAM
ACE CCTTCCCGCTACAACTATGACT GGACAACCGGAGGACAGATC ATACTTGGTTCGAAGATACC FAM
AT1R (bovine) TaqMan gene expression assays (Assay ID Bt03213473_m1; part number 4331182; reporter sequence
AGGTCTGCATCCAGGTGCATTTGGC)
FAM
AT2R CTGTCATTTACCCCTTTCTGTCTCA CAGACAAGCCATACACCAAACAAG TTGCCAGGGATTTCT FAM
Glyceraldehyde
3-phosphate
dehydrogenase
GCTACACTGAGGACCAGGTT AGCATCGAAGGTAGAAGAGTGAGT CTCCTGCGACTTCAAC FAM
Cyclophilin A GGTTCCTGCTTTCACAGAATAATTCC GTACCATTATGGCGTGTGAAGTCA CACCCTGGCACATAAA FAM
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sone comparedwith those from the saline-treated ewes (P
.05) (Table 2). There were no significant differences in
plasma concentrations of angiotensinogen, renin or T4 be-
tween the 2 groups of fetuses (Table 2 and Figure 1A).
Pulmonary ACE mRNA and ACE concentration were
significantly greater in the fetuses exposed to dexametha-
sone compared with the control fetuses (P  .05) (Figure
2A).ThemRNAlevels ofACE in the fetal kidneyandheart
were also elevated by maternal dexamethasone treatment
(P  .05) (Figures 3A and 4A), although renal ACE con-
centrationwasunchangedandcardiacACEconcentration
was below the limit of assay detection in both groups of
fetuses (0.10 nmol min1 per mg protein1) (Figure 3A).
Neither relativemRNAabundance nor protein content
for AT1R and AT2R in the lungs and kidneys were signif-
icantly different between fetuses of mothers treated with
dexamethasone or saline (Table 3). Renal renin mRNA
abundance was also unchanged by maternal dexametha-
sone treatment (Table 3). In the fetal heart, no significant
changes inAT1RmRNA level, or protein content of AT1R
or AT2R, were seen after maternal dexamethasone treat-
ment, although cardiac AT2R mRNA abundance was re-
duced in the fetuses exposed to dexamethasone (Table 3
and Figure 4B; P  .05).
When observations from all of the fetuses were consid-
ered, a significant positive correlation was observed be-
tween pulmonary ACE concentration and circulating
ACE levels (r  0.77, P  .001, n  10). Significant
negative correlations were observed between plasma cor-
tisol concentration and both pulmonary ACE mRNA
abundance and plasmaACE concen-
tration (Table 4). Plasma renin con-
centration was negatively correlated
with plasma ACE concentration in
the fetuses (Table 4). In addition,
plasma T3 correlated with circulat-
ing and pulmonary ACE concen-
trations, and with ACE mRNA
abundance in the fetal lungs, kid-
neys, and heart (Table 4). Signifi-
cant positive relationships were
also seen between plasma insulin
concentration and various compo-
nents of the fetal RAS (Table 4).
Partial correlation analyses showed
that pulmonary ACE concentration
and renalACEmRNAwerepositively
associated with plasma T3 concentra-
tion (r0.67, P .05, n 10 and
r  0.72, P  .05, n  10, respec-
tively), independent of plasma insulin;
all other partial correlations failed to
identify a single significant independent
factor when multiple hormones corre-
lated with RAS components.
Figure 2. Pulmonary ACE mRNA and concentration in the fetus (A) and ewe (B) at 10 hours
after saline (, n  5) or dexamethasone ( , n  5) treatment. Data are presented as mean
values (SEM); transcript data are presented as fold changes relative to the saline-treated group.
Significant difference from saline-treated group: *, P  .05.
Table 2. Plasma Concentrations of Cortisol, Thyroid Hormones (T4 and T3), and Insulin in the Ewes and Fetuses at
10 Hours After Saline or Dexamethasone Treatment
Ewe Fetus
Saline Dexamethasone Saline Dexamethasone
Cortisol (ng mL1) 57.8  12.2 3.2  0.1a 16.1  2.8 10.0  1.4a
T3 (ng mL
1) 1.13  0.08 0.69  0.06a 0.28  0.06 0.70  0.08a
T4 (ng mL
1) 52.1  10.6 21.8  5.3a 132.5  11.7 115.0  21.3
Insulin (ng mL1) 0.19  0.08 0.27  0.05 0.25  0.05 1.35  0.31a
Data are presented as mean values (SEM).
a Significantly different from saline-treated group, P  .05.
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Ewe
In the ewes treatedwith dexamethasone, plasma con-
centrations of cortisol, renin, T3, and T4 were sup-
pressed, and plasma insulin increased, within 10 hours
of the second injection (Table 2 and Figure 2B; P .05).
Plasma angiotensinogen concentration was increased
by dexamethasone administration, but this just failed to
reach statistical significance (P  .059) (Figure 1B).
Maternal dexamethasone treatment had no significant
effect on plasma ACE concentration (Figure 1B).
Pulmonary ACE concentration was increased in the
dexamethasone-treated ewes comparedwith those treated
with saline (P  .05) (Figure 2B).
However, there was no significant
effect of dexamethasone administra-
tion on ACE mRNA abundance in
the maternal lungs (Figure 2B). Re-
nal ACE mRNA and ACE concen-
trationswere also unchanged byma-
ternal dexamethasone treatment
(Figure 3B). Maternal dexametha-
sone treatment had no significant ef-
fect on the gene transcript or protein
levels of theAII receptors in the lungs
and kidneys, or renin mRNA abun-
dance in the kidneys of the pregnant
ewes (Table 3).
Using data from all ewes, signif-
icant inverse correlations were ob-
served between pulmonary ACE
concentration and plasma concen-
trations of both cortisol (r 
0.89, P  .001, n  10) and T4
(r0.80, P .005, n 10). Par-
tial correlation analyses showed
that pulmonary ACE concentra-
tion was inversely associated with
plasma T4 concentration (r 
0.74, P .05, n 10), independent of plasma cortisol
concentration. Plasma renin concentration was corre-
lated with renal renin mRNA abundance (r  0.70,
P  .05, n  10) in the pregnant ewes. Significant pos-
itive relationships were also seen between plasma T3
concentration and both renal renin mRNA abundance
(r  0.67, P  .05, n  10) and plasma renin con-
centration (r  0.75, P  .01, n  10).
Discussion
Effects of maternal
dexamethasone treatment on
the RAS in utero
The present study demonstrates
for the first time that maternal dexa-
methasone treatment, at a dose
equivalent to that used in clinical
practice, alters various components
of the RAS in both the pregnant ewe
and fetus. Administration of the syn-
thetic glucocorticoid up-regulated
ACE mRNA abundance in a variety
of fetal tissues; it also increased pul-
monaryACEconcentration inboth the
Figure 3. Renal ACE mRNA and concentration in the fetus (A) and ewe (B) at 10 hours after
saline (, n  5) or dexamethasone ( , n  5) treatment. Data are presented as mean values
(SEM); transcript data are presented as fold changes relative to the saline-treated group.
Significant difference from saline-treated group: *, P  .05.
Figure 4. Cardiac ACE (A) and AT2R (B) mRNA levels in the fetus at 10 hours after saline (, n 5)
or dexamethasone ( , n 5) treatment. Data are presented as mean fold changes (SEM) relative
to the saline-treated group. Significant difference from saline-treated group: *, P .05.
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pregnant ewe and fetus andACE concentration in the fetal cir-
culation.Inthepregnantewe,plasmaangiotensinogentended
to increase in response to dexamethasone administration,
and plasma renin was suppressed, which suggested negative
feedback control by activation of the AT1R in the kidney.
In the present study, the increments in circulating and
pulmonary ACE concentrations observed in the fetuses
after maternal dexamethasone treatment were similar to
those seen previously in sheep fetuses infused directlywith
the synthetic glucocorticoid (23). In addition, both fetal
and maternal routes of dexamethasone administration
hadno significant effect on renalACEconcentration in the
sheep fetus (23). The present findings indicate that mater-
nal dexamethasone treatment elevatedpulmonaryandcir-
culating ACE concentration in utero, at least in part, by
increasing ACE mRNA abundance in the lungs and other
fetal tissues.At10hours after the second injectionofdexa-
methasone to the pregnant ewe, ACE mRNA levels in the
fetal kidney and heart had increased without any change
in enzyme concentration. The duration of exposure to the
synthetic glucocorticoid, and/or the timing of tissue col-
lection, however, may have been too short to observe sig-
nificant effects on protein translation in these fetal organs.
The changes in plasma and pulmonary ACE concen-
tration, and cardiac ACEmRNA, induced in utero byma-
ternal dexamethasone treatment were similar to the nor-
mal maturational changes seen in sheep fetuses close to
term (22, 33). In the lungs, ACE is localized to the vascular
endothelium and for most of gestation, both pulmonary
blood flow and ACE concentration in the fetal lungs are
relatively low. However, pulmonary ACE concentration
in the fetus increases near term and this appears to be
drivenby theprepartumglucocorticoid surge aspart of the
preparation for extrauterine life (22). Neonatal plasma
Table 4. Correlation Coefficients From Relationships Between Plasma Hormone Concentrations in the Fetuses, and
ACE mRNA and Concentrations in the Fetal Circulation and Tissues
Plasma
ACE
Lung ACE
mRNA
Lung ACE
Concentration
Kidney ACE
mRNA
Kidney ACE
Concentration
Heart ACE
mRNA
Cortisol 0.71a 0.67a NS NS NS NS
T3 0.63
a 0.81b 0.82b 0.84b NS 0.88b
Insulin 0.75a 0.80a 0.66a 0.65a 0.69a NS
Renin 0.72a NS NS NS NS NS
NS, not significant. Pearson correlation, n  10.
a P  .05.
b P  .005.
Table 3. Relative Protein and mRNA Levels of Renin, AT1R, and AT2R in Fetal and Maternal Lung and Kidney at 10
Hours After Saline or Dexamethasone Treatment
Ewe Fetus
Saline Dexamethasone Saline Dexamethasone
Lung mRNA
AT1R 1.00  0.29 1.69  0.50 1.00  0.25 1.57  0.25
AT2R 1.00  0.79 2.21  1.15 1.00  0.22 1.56  0.43
Lung protein
AT1R 1.00  0.33 1.09  0.26 1.00  0.05 1.19  0.09
AT2R 1.00  0.08 1.03  0.15 1.00  0.15 1.15  0.17
Kidney mRNA
Renin 1.00  0.24 0.53  0.19 1.00  0.33 1.37  0.50
AT1R 1.00  0.51 0.76  0.29 1.00  0.43 1.11  0.49
AT2R 1.00  0.59 0.21  0.06 1.00  0.40 0.57  0.23
Kidney protein
AT1R 1.00  0.08 0.99  0.07 1.00  0.11 0.95  0.10
AT2R 1.00  0.08 1.16  0.08 1.00  0.10 1.21  0.13
Heart mRNA
AT1R NA NA 1.00  0.28 1.20  0.19
AT2R NA NA 1.00  0.16 1.23  0.09
Heart protein
AT1R NA NA 1.00  0.10 1.15  0.07
AT2R NA NA 1.00  0.21 0.34  0.11
a
Data are presented as mean fold changes (SEM) relative to the saline-treated group. NA, not available.
a Significant difference from saline-treated group, P  .05.
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AII concentrations after vaginal delivery are much higher
than after caesarean section in human infants (34), sug-
gesting that the capacity to convert AI to AII is activated
by exposure to endogenous glucocorticoids before birth in
preparation for pulmonary vasodilatation and increased
pulmonary blood flow and delivery of AI after birth.
Developmental changes in AII receptor expression are
also seen in the fetus towards term.Therelativeexpressionof
AII receptor subtypes in a variety of fetal tissues shifts with
gestational age fromwidespreadAT2R abundance to tissue-
specific and predominant localization of AT1R (35). In the
heart of the sheep fetus, mRNA abundance and receptor
density of the AT2R receptor are high from at least midges-
tation and decrease over the perinatal period (36, 37). The
reduction in cardiac AT2R mRNA level induced by dexa-
methasone in the present study indicates that the normal
developmental decline in AT2R expression seen in the fetal
heart near term may be a glucocorticoid-dependent event.
Mechanisms of glucocorticoid action on the RAS
The mechanisms of glucocorticoid action on the RAS in
the pregnant ewe and fetus may be direct and/or indirect
involving coincident changes in other endocrine systems,
such as insulin and the thyroid hormones. The effects of an-
tenatal glucocorticoid treatment on the RAS observed in the
present studyareunlikely tobe theconsequenceof fetalhypox-
aemia or hypotension. In the chronically catheterized pregnant
ewe and fetus, the same protocol of maternal dexamethasone
treatmentdoesnot influence fetal bloodgas status andcauses a
small, but significant, rise in arterial BP (26, 38).
Dexamethasonemayhavedirect effects on the genes for
angiotensinogen, ACE and the AT2R. A glucocorticoid-
response element in the angiotensinogen gene is an im-
portant regulator of angiotensinogen synthesis (39); thus,
the near-significant rise in maternal plasma angiotensino-
gen may have been directly stimulated by dexamethasone
treatment. Glucocorticoid-response elements have also
been identified close to a promoter region in the murine
and human ACE gene (40), and dexamethasone has been
shownpreviously topromoteACEmRNAabundance and
enzyme activity in rabbit alveolar macrophages, bovine
pulmonary artery endothelial cells and rat cardiac fibro-
blasts studied invitro (41–43).Moreover, dexamethasone
increases ACE mRNA abundance and enzyme activity in
cultured rat aortic smooth muscle cells by stabilization of
mRNAaswell as enhancedgene transcription (44). In rats,
multiple glucocorticoid-response elements are localized
near to the regulatory regionof theAT2Rgene,whichhave
inhibitory influences on promoter activity and AT2R gene
expression (45). Indeed, AT2R mRNA and protein levels
in hearts isolated from fetal rats are suppressed by 48
hours of dexamethasone treatment in vitro (45).
The present study was part of a larger project examin-
ing the effects of maternal dexamethasone treatment on
fetal growth and development and in which plasma con-
centrationsof insulin and the thyroidhormonesweremea-
sured (12, 30). Significant associations were observed be-
tween circulating concentrations of T3 in the fetus and
plasma and pulmonaryACE concentrations, and the tran-
script levels of ACE in the fetal lungs, kidneys, and heart.
These findings support the suggestion that T3may have an
important role in mediating the regulatory effects of glu-
cocorticoids on tissue and circulating ACE expression in
utero (46). Indeed, in fetal sheep, experimental thyroid
hormone deficiency prevents the normal developmental
rise in pulmonary and renalACE concentration near term,
and exogenous T3 infusion has been shown to increase
ACE concentration in the fetal lungs, but not kidneys (46).
Previous studies, however, have shown that maternal
dexamethasone treatment has differential effects on the
thyroid hormone axis in the pregnant ewe and fetus (12).
In the sheep fetus, synthetic and endogenous glucocorti-
coids activate theproductionofT3,whereas in themother,
the thyroid hormone axis is suppressed (11, 12). There-
fore, the rise in pulmonary ACE concentration seen in the
pregnant ewe treated with dexamethasone may be the di-
rect consequence of glucocorticoid, rather thanT3, action.
Alternatively, dexamethasone and/or T3 may have differ-
ent and tissue-specific effects on ACE expression in the
fetus andmother. In adult rats, dexamethasone treatment
causes a rise in ACE concentration in the lungs, but not
renal cortex or medulla, and T3 administration reduces
pulmonary ACE, while increasing renal and circulating
ACE, concentrations (47).
Implications of altered RAS activity induced by
maternal dexamethasone treatment
Changes in the activity of theRAS in utero aftermaternal
dexamethasone treatmentmay contribute to thematuration
offetal tissues inducedclinicallybysyntheticglucocorticoids.
In addition, alterations in fetal RAS activity may have both
local andendocrine effects ongrowthandmaturationbefore
birth (48). Although a limitation of this study was that cir-
culating and tissue concentrations of AII, and downstream
signalingpathways,werenotdetermined, the increase inpul-
monary ACE concentration is likely to result in enhanced
production of AII locally in the lungs of the ewe and fetus.
Local production of AII in the fetal lungs has been shown to
promote maturation of pulmonary structure, including vas-
cularization and airway branching (49, 50), and may medi-
ate, in part, some of the beneficial effects of antenatal syn-
thetic glucocorticoids on the developing lungs.
Activation of ACE mRNA, and suppression of AT2R
mRNA, abundances in the fetal heart by dexamethasone
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may influence the development of cardiac structure and
function in utero, if the mRNA levels were to translate to
altered protein expression in the longer term. The devel-
opmental processes of growth and differentiation in fetal
cardiomyocytes are sensitive to glucocorticoids and thy-
roid hormones (51), and the mechanisms of hormone ac-
tion may involve changes in local AII activity (52, 53). It
is increasingly recognized that, whereas antenatal syn-
thetic glucocorticoid treatment can be life-saving for the
infant when delivery occurs preterm, there may also be
adverse sequelae reaching into adulthood (54). Indeed,
dexamethasone-induced changes in the fetal RAS, espe-
ciallywithin the heart and kidney,may have consequences
for the regulation of arterial BP in both fetal and postnatal
life. In fetal sheep, exposure to dexamethasone either by
direct fetal infusion or by maternal treatment causes an
increase in arterial BP and modifies the cardiovascular
responses to hypoxaemia induced experimentally in utero
(23, 26, 38). Previously, arterial BPwas found to correlate
with pulmonary ACE concentration in sheep fetuses in-
fused with either dexamethasone or saline (23). Pulmo-
nary ACE is responsible both for the production of vaso-
constrictive AII and for the degradation of the vasodilator
bradykinin, and the RAS is known to have an important
role in the control of fetal BP by peripheral and central
mechanisms (55–57). Furthermore, the RAS has been im-
plicated in the developmental programming of hyperten-
sion in sheep and rodent offspring exposed to glucocor-
ticoids in utero (58–60). In conclusion, antenatal
dexamethasone treatment stimulates components of the
maternal and fetalRAS, and suppresses fetal cardiacAT2R
mRNA levels, in the sheep. These changes may influence
maturation of the developing lungs, heart, and kidney and
may have acute and long-term consequences for the reg-
ulation of arterial BP.
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